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Noninvasive imaging of 
radiolabeled exosome-mimetic 
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Na Eun Choi1, Hyun Jeong Oh1,2, Seunggyun Ha1,2, Yun-Sang Lee1,2, Jae Min Jeong1, 
Yong Song Gho3 & Dong Soo Lee1,2
Exosomes known as nano-sized extracellular vesicles attracted recent interests due to their potential 
usefulness in drug delivery. Amid remarkable advances in biomedical applications of exosomes, it is 
crucial to understand in vivo distribution and behavior of exosomes. Here, we developed a simple 
method for radiolabeling of macrophage-derived exosome-mimetic nanovesicles (ENVs) with 99mTc-
HMPAO under physiologic conditions and monitored in vivo distribution of 99mTc-HMPAO-ENVs using 
SPECT/CT in living mice. ENVs were produced from the mouse RAW264.7 macrophage cell line and 
labeled with 99mTc-HMPAO for 1 hr incubation, followed by removal of free 99mTc-HMPAO. SPECT/CT 
images were serially acquired after intravenous injection to BALB/c mouse. When ENVs were labeled 
with 99mTc-HMPAO, the radiochemical purity of 99mTc-HMPAO-ENVs was higher than 90% and the 
expression of exosome specific protein (CD63) did not change in 99mTc-HMPAO-ENVs. 99mTc-HMPAO-
ENVs showed high serum stability (90%) which was similar to that in phosphate buffered saline until 
5 hr. SPECT/CT images of the mice injected with 99mTc-HMPAO-ENVs exhibited higher uptake in liver 
and no uptake in brain, whereas mice injected with 99mTc-HMPAO showed high brain uptake until 
5 hr. Our noninvasive imaging of radiolabeled-ENVs promises better understanding of the in vivo 
behavior of exosomes for upcoming biomedical application.
Exosomes are nano-sized extracellular vesicles which are produced by most of the cell types. Exosomes 
carry a subset of genetic materials and proteins to play key roles in delivery of the biological information 
between cells1,2. Since exosomes were found initially to play a role in disposing unnecessary proteins such 
as transferrin receptor during reticulocyte maturation 30 years ago, a variety of functional roles have 
been elucidated3,4. Especially, recently-alleged biological roles of exosomes ranged from their involve-
ment in normal physiologic functions such as stem cell maintenance, immune modulation and tissue 
homeostasis to their contribution to the pathophysiology of several diseases5. In addition, exosomes also 
delivered variable sets of bioactive materials specific for parent cell-types and mediated cellular activities 
of recipient cells6.
Exosomes can be used as drug carriers by applying their role of in vivo intercellular communication. 
As natural endogenous nanoparticles, the autologous exosomes have the advantages of immune-tolerance 
and stability in circulation systems7. In addition, exosomes derived from different cells have target-specific 
homing effect even to achieve active targeting8,9. To enhance their targeting potency, ex vivo cell-derived 
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exosomes were engineered to carry specific surface proteins10. According to these advantages, ex vivo 
cell-derived exosomes were tried to be used as nanocarriers. For example, exosomes were used to target 
cancer tissue by transporting therapeutic nucleic acids in animal experiments11. Even in the clinical 
setting, cancer antigen-pulsed autologous exosomes isolated from patients were already applied for can-
cer immunotherapy12,13. However, one major drawback of exosome-based nanocarriers was the small 
amount of natural exosomes. This low yield limits in vivo application where large amount of exosomes 
are necessary.
Recently exosome-mimetic nanovesicles (ENVs) were collected from whole cells as alternatives to 
the natural exosomes also collected from the cells14. This exosome-mimetic technology overcame several 
limitations of natural exosomes for the application of practical drug delivery, which included low yield 
(0.3 to 0.5 μ g of exosomes per 106 dendritic cells in 24 h)15 and difficulties in purification process16. 
These ENVs have similar characteristics with natural exosomes in terms of size, morphology and protein 
contents. ENVs were easily produced with 100-fold higher amount than naturally collected exosomes, 
which enabled therapeutic application14. In addition, ENVs shared the similar homing properties to the 
natural exosomes, which was revealed by showing accumulation of macrophage-derived ENVs in the 
tumors visualized by in vivo fluorescence imaging14.
Considering that there is a variety of cell-type specific exosomes, in vivo behaviors of these exosomes 
may be highly varied. However, there were very few effective methods reported to investigate the in 
vivo behavior of these exosomes, which also became an obstacle for the biomedical application of these 
exosomes or ENVs. A breakthrough to investigate in vivo distribution and trace the exosomes is highly 
desired. To date, fluorescence imaging was tried to trace the whereabouts of the exosomes and to inves-
tigate the distribution of cell-derived membrane vesicles17–20. Although in vivo optical imaging is a simple 
tool for in vitro and in vivo study, it has intrinsic limitations including difficulties in quantification and 
poor tissue penetration depth. Radioisotope (RI) labeling and nuclear imaging can easily overcome these 
limitations and can be applied to trace exosomes in vivo21,22.
In this study, we developed a simple radiolabeling method for ENVs with 99mTc- hexamethylpro-
pyleneamineoxime (HMPAO) under physiologic condition, and visualized in vivo distribution of 
99mTc-HMPAO-ENVs using SPECT/CT. A scheme for radiolabeling of ENVs using 99mTc-HMPAO was 
summarized in Fig. 1. 99mTc-HMPAO is known as uncharged and highly lipophilic radiotracer, which has 
been widely used for cell labelling. It is well known that intracellular glutathione converts 99mTc-HMPAO 
to the hydrophilic form to be trapped inside cells. Based on this property, 99mTc-HMPAO has been 
clinically used for white blood cell (WBC) labeling for inflammation imaging23. Since 99mTc-HMPAO is 
an easily accessible radiotracer in the clinical setting, our approach is expected to facilitate biomedical 
application of exosomes by easily disclosing the whereabouts of exosomes or ENVs.
Results
Radiolabeling of ENVs with 99mTc-HMPAO. ENVs produced from mouse Raw 264.7 macrophage 
cell line were purified from interface layer through OptiPrep density gradient fractionation. When we 
measured glutathione in ENVs for 99mTc-HMPAO labeling, we found 3.15 ± 0.16 nmol of glutathione in 
0.1 mg of ENVs (Supplementary Fig. 1).
ENVs were incubated with 99mTc-HMPAO for labeling under mild condition (in pH 7, PBS buffer) 
in order to prevent the labeled-ENVs from unexpected aggregation. After labeling, purification was per-
formed in two methods to remove free 99mTc-HMPAO, as described in Methods. Radiochemical purity 
was 99.6 ± 3.3% after the size exclusion column was applied (Fig.  2a), and 93.7 ± 5.4% after purifica-
tion with exosome exclusive spin column with centrifugation. The procedure time of exosome-spine 
Figure 1. Schematic diagram for radiolabeling method of 99mTc-HMPAO-exosome nanovesicles (ENVs). 
99mTc-hexamethylpropyleneamineoxime (HMPAO) was chosen as one of the proper radiotracers for exosome 
labeling. After highly lipophilic 99mTc-HMPAO enters the ENVs, endogenous glutathione in ENVs begins to 
convert 99mTc-HMPAO to hydrophilic form, which is trapped inside ENVs.
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column method was 3 min, which was 10 times less than the size exclusion column method (Table 1). 
Considering both methods showed comparable radiochemical purity while exosome exclusive spin col-
umn method took less time, the exosome-spin column method was used for further characterization 
study, SPECT/CT imaging and ex vivo biodistribution study.
Characterization of ENVs after 99mTc-HMPAO radiolabeling. Size distribution of unlabeled 
ENVs and 99mTc-HMPAO-ENVs was measured using nanoparticle tracking analysis (NTA). The aver-
age diameter of unlabeled ENVs was 218 ± 8.2 nm, and that of 99mTc-HMPAO-ENVs was 213 ± 6.8 nm 
(Fig. 2b), showing no significant changes after 99mTc-HMPAO radiolabeling. In order to confirm whether 
the exosome-specific protein contents of ENVs changed after 99mTc-HMPAO radiolabeling, an exosomal 
marker, CD63, was measured by western blot analysis. Amount of protein in 99mTc-HMPAO-ENVs did 
not change, showing high expression of CD63 similar to that in unlabeled ENVs (Fig. 2c). We performed 
the serum stability test for 99mTc-HMPAO-ENVs. 99mTc-HMPAO-ENVs showed comparable serum sta-
bility with that in PBS, maintaining around 90% until 5 hr (Fig. 2d).
In vivo SPECT/CT images and biodistribution of 99mTc-HMPAO-ENVs. In vivo imaging of 
99mTc-HMPAO-ENVs and 99mTc-HMPAO were acquired by SPECT/CT. Within 30 min after injection, 
99mTc-HMPAO-ENVs were taken up mainly by the liver and spleen (Fig. 3a). Of note, no significant brain 
Figure 2. Radiochemical purification of 99mTc-HMPAO-ENVs and characteristics. (a) 99mTc-HMPAO 
and 99mTc-HMPAO-ENVs were analyzed by instant thin layered chromatography (ITLC) using Whatman 
No. 1 paper. The radiochemical purify was analyzed right after removing 99mTc-HMPAO. The radiochemical 
purify was more than 95%. (b) Average size distribution of non-labeled ENVs and 99mTc-HMPAO-ENVs 
was examined by nanoparticle tracking analysis (NTA). There was no significant difference for the size 
distribution between non-labeled ENVs and 99mTc-HMPAO-labeled ENVs. (c) An exosomal marker, CD63, 
was measured to check ENVs before and after 99mTc-HMPAO radiolabeling by Western blot. Amount of 
exosomal protein in its expression was not changed, showing high expression of CD63 which was similar 
with protein expression in unlabeled ENVs. (d) Stability of 99mTc-HMPAO-ENVs was examined in human 
serum and PBS. The level of stability was analyzed by ITLC.
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uptake was observed, compared with the significant brain accumulation in the mice with 99mTc-HMPAO-only 
administration at 30 min images (Fig. 3b). At 3 hr after the injection, 99mTc-HMPAO-ENVs accumulated 
in the salivary glands. In contrast, in the mice with 99mTc-HMPAO-only administration, radioactivity was 
relatively low in the liver and spleen, and this radioactivity decreased gradually until 5 hr (Fig. 3b). The 
intense uptake in the brain and intestine was observed immediately after the injection and the activity 
was remained until 5 hr. Salivary gland uptake was high in 99mTc-HMPAO-only administered group. 
Quantitative volume-of-interest analysis based on SPECT/CT images revealed similar distribution pat-
tern to visual findings (Supplementary Fig. 2).
We additionally acquired SPECT/CT imaging of 99mTc-HMPAO-ENVs obtained from HB1.F3 human 
neural stem cells to test whether this method could be used in different type of cells. Just like the ENVs 
obtained from Raw 264.7 macrophage cells, the ENVs from neural stem cells showed the similar stability 
in the serum, and after systemic administration, they accumulated in the liver and spleen within 30 min 
and the uptakes in salivary glands increased gradually (Supplementary Fig. 3a,b). We also performed 
production of natural exosomes using Raw 264.7 macrophage cells and labeled them with the same 
method. After 3 weeks of culture and preparation, we could produce half the amount of exosomes than 
the ENVs, and SPECT/CT disclosed the distribution of 99mTc-HMPAO labeled natural exosomes. Low 
sensitivity due to lower amount of exosomes and radioactive label than ENVs made the images poor, 
Methods *Procedure time
**Radiochemical purity (%) 
(n = 3/group)
Elution over PD-10 
column 30 min 99.6± 3.3
Centrifugation with 
exosome exclusive 
spin column
3 min 93.7± 5.4
Table 1.  Radiochemical purity and protocol time for each isolation method. *Procedure time: the time 
point until 99mTc-HMPAO-ENV was produced after the purification via size exclusion PD-10 column or 
exosome exclusive spin column. **Radiochemical purity: the measured % values by ITLC using Whatman 
no. 1 paper and 0.9% w/v NaCl solution as an eluent. Radiochemical purity was determined by following 
equation: E(%) = (1 − radioactivity of supernatant)/total radioactivity × 100%.
Figure 3. In vivo SPECT/CT images of 99mTc-HMPAO-ENVs injected in mice. After intravenous injection 
of 99mTc-HMPAO-ENVs or 99mTc-HMPAO, SPECT/CT images were acquired at 30 min, 3 hr, and 5 hr in 
BALB/c mice. (a) The SPECT/CT imaging showed the significantly intense uptake of 99mTc-HMPAO-ENVs 
in the liver and radioactivity in the salivary glands and intestine until 5 hr. (b) In contrast, high brain uptake 
and the delayed salivary glands uptake were observed in 99mTc-HMPAO-injected mouse group.
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but accumulation pattern was similar to that of ENVs at 3 hr. 99mTc-HMPAO labeled natural exosomes 
accumulated in liver and spleen and then bowel (Supplementary Fig. 3c).
Mice were sacrificed after 0.5, 1, 3, and 5 h of 99mTc-HMPAO-ENVs to investigate in vivo distribution 
using ex vivo quantitation of radioactivity. The distribution pattern was different particularly in the liver 
and brain between 99mTc-HMPAO-ENVs and 99mTc-HMPAO-only administered groups (Fig. 4).
Discussion
Exosome-based drug delivery receives great attention owing to merits as a naturally obtained nanopar-
ticle which is able to bypass many issues of nanoparticles including immune activation, off-target effect 
and in vivo degradation6. Although cell-derived exosomes have showed therapeutic effects on specific 
inflammatory or cancer condition14,24, it remains unknown whether the injected exosomes are effectively 
delivered to the target tissue. To achieve breakthrough in exosome-based therapy, in vivo imaging is 
necessary.
In this study, we carried out radiolabeled-exosome imaging using ENVs which share biological fea-
tures with naturally derived exosomes14. To investigate whereabouts and kinetics of administered ENVs 
or exosomes, imaging should be performed in living animals which can provide quantitative information 
even of the deep organs. Since exosomes are natural nanoparticles, distinct from artificially-made nano-
particles, labeling should be performed under biologically-inert and conservative condition. Until now, 
in previous studies fluorescence reporters or highly lipophilic dyes were used to track the in vitro and in 
vivo behavior in cells or living animals17,25,26. These methods had intrinsic limitations in light penetration 
depth and quantitation. MRI can overcome the disadvantage of optical imaging and modified liposomes 
were proposed as artificial exosomes which were constructed to contain surface markers and super par-
amagnetic labels for magnetic resonance imaging27, however, there was no suggestion how to make 
exosomes or ENVs with paramagnetic materials. Radionuclide labeling and imaging could be an alter-
native because of their high sensitivity, noninvasiveness and quantification of biodistribution. Moreover, 
ex vivo biodistribution study using radioactivity as we employed in this study accurately provides the 
absolute information of whereabouts after sacrifice of the animals even in the small organs with high 
sensitivity. To our knowledge, two studies have tried to develop radioisotope-labeled exosome to evalu-
ate biodistribution, however, they only showed ex vivo biodistribution and a study engaged streptavidin 
reporter which needed genetically modified cells21,22. To achieve in vivo radionuclide-labeled exosome 
imaging under physiologic condition, we employed 99mTc-HMPAO. By reaction of 99mTc-HMPAO with 
sulfhydryl groups of the glutathione abundantly existing in cells, 99mTc-HMPAO became hydrophilic 
compounds and trapped within cells. Because of this property, ENVs composed of lipid bilayer were 
expected to be simply labeled with 99mTc-HMPAO under physiologic condition. This approach was intro-
duced in glutathione-contained liposome labeling and was used for liposome imaging28,29. As liposomes 
and exosomes consist of lipid bilayer, and moreover, exosomes had glutathione inside the exosomes or 
ENVs, the 99mTc-HMPAO labeling resulted in comparable excellent radiochemical purity (higher than 
95%). Furthermore, approximately 90% of entrapped 99mTc in ENVs persisted within the exosomes and 
ENVs in the serum until 5 hr. When erythrocytes and platelets were labeled with 99mTc-HMPAO, spon-
taneous release rate for 1 h ranged from 5% to 10%30,31, which corresponded to that of ENVs.
99mTc-HMPAO labeling for ENVs could be performed under physiologic condition not to change 
their properties. In the in vitro study, CD63, an exosome marker, did not change after labeling. We also 
found that average size distribution did not change after labeling of ENVs with 99mTc-HMPAO. A small 
Figure 4. Biodistribution of 99mTc-HMPAO-ENVs. Mice were sacrificed at 0.5, 1, 3, 5 hr after 99mTc-
HMPAO ENVs injection and radioactivity was measured for quantitative analysis of biodistribution (n = 4 
for groups sacrificed at 0.5, 1 and 5 hr; n = 3 for a group sacrificed at 3 hr). As shown in SPECT images, 
99mTc-HMPAO-ENVs were highly accumulated in liver, spleen and kidneys. Note that no significant uptake 
in brain unlike 99mTc-HMPAO used as a brain perfusion tracer. %ID/g represents counts of radioactivity 
normalized by injected dose and weights of organ. Data are presented as mean ± S.D.
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fraction of ENVs which were smaller than average size was identified after labeling (Fig. 2b), which could 
mean that a small portion of ENVs would have been damaged during labeling procedures. Fortunately, 
the overall size distribution was the same after the procedures. In the previous our work (unpublished), 
ENVs were modified with SCN-Bn-NOTA, which is a bifunctional chelating agent, and then labeled 
with 68Ga. After the 68Ga labeling, the size of ENVs increased up to 530 nm probably due to aggregations 
which resulted in the accumulation in lung (Supplementary Fig. 4). We speculated that labeling condition 
was closely related to aggregations and labeling for ENVs absolutely need the physiologic condition. In 
this study, the size of 99mTc-HMPAO-labeled ENVs did not dramatically change as in 68Ga labeling after 
labeling. In vivo SPECT/CT images of 99mTc-HMPAO-ENVs proved no lung accumulation suggesting 
negligible aggregations during labeling procedures and in vivo after systemic injection.
In this study, we adopted two different purification methods based on either size exclusion column or 
exosome exclusive spin column. Both methods showed comparable labeling efficiency with rapid radio-
labeling time, but in the case of size exclusion column method, large amount of ENVs was lost during 
elution. In addition, the size exclusion column method takes 10 times longer until final elution than spin 
column-based centrifugation (30 min vs. 3 min, Table  1). Although the loading volume of exosome in 
spin column is limited (< 100 μ l), we suggest that spin column-based centrifugation would be a better 
method of radiolabeled ENVs isolation in terms of rapid and high yield of 99mTc-HMPAO-ENVs.
We found that 99mTc-labeled-ENVs could provide sensitive, quantitative and reproducible imaging. 
99mTc-HMPAO-ENVs administrated mouse showed high accumulation of injected ENVs in liver and 
spleen at 30 min, which was about 2–3 folds higher than 99mTc-HMPAO-only administered mouse. The 
uptake of 99mTc-HMPAO-ENVs in the liver and spleen could be a result of phagocytosis in mononuclear 
phagocyte systems. Since ENVs in our experiments were derived from mouse macrophage cells, they 
could be actively captured by host-derived cells abundant in liver and spleen32. SPECT/CT images of 
99mTc-HMPAO-ENVs obtained from human neural stem cells revealed similar accumulation pattern to 
those obtained from Raw 264.7 cells. Besides, similar-sized liposomes were reported to accumulate pas-
sively in mononuclear phagocyte systems33, and thus, the accumulation mechanism of ENVs might be 
soon understood. Distribution study of natural exosomes was also feasible though the yield of exosomes 
was not sufficient for radiolabeling and purification. To obtain SPECT/CT images of natural exosomes, 
large amount of cells were needed to obtain minimum amount of natural exosomes. Despite this dif-
ficulty, we found that radiolabeled natural exosomes also showed similar distribution to radiolabeled 
ENVs derived from macrophage and neural stem cells.
99mTc-HMPAO-ENVs imaging will be useful for in vivo drug-delivery monitoring. In biodistri-
bution study, brain uptake was not observed in 99mTc-HMPAO-ENVs administration group, whereas 
the 99mTc-HMPAO-only injected group showed high accumulation in the brain corresponding to pre-
vious study regarding in vivo kinetics of 99mTc-HMPAO34. Radioactivity of salivary glands and bowel 
walls appeared at 3 hr and 5 hr in 99mTc-HMPAO-ENVs administration group like 99mTc-HMPAO-only 
injected group, which might correspond to in vitro stability of 99mTc-HMPAO-ENVs, a result of eluted 
99mTc-compounds from ENVs. Moreover, the release of 99mTc-compounds might be facilitated in vivo 
due to phagocytosis in mononuclear phagocyte systems. These biodistribution patterns suggested 
99mTc-HMPAO-ENVs can be used for tracing, particularly in early phase, considering that no brain 
and minimal salivary gland uptake was detected. In the future, because of eluted 99mTc-compounds, accu-
mulation of ENVs in target tissue should be carefully interpreted as in 99mTc-HMPAO-labeled leukocyte 
imaging in the routine clinical setting35.
As exosomes are derived from biological tissues, they potentially have advantages in clinical use for 
diagnostic imaging as well as drug carriers. Many researchers have tried to exploit exosomes as poten-
tial drug delivery nanocarriers to transport chemical drug or siRNA to the disease site7,36. In spite of 
the limitations in delayed spontaneous release of 99mTc-compounds, our approach has a wide range of 
applications involving brain targeting, cancer and inflammation imaging. Radiolabeled-exosomes can be 
used to track in vivo behavior of exosomes to find out where the administrated exosomes is localized 
and how long exosomes is retained in the target tissue. Therefore, it can contribute to understanding 
pharmacokinetics of the drug-loaded exosomes. Furthermore, in vivo imaging of exosomes derived from 
several types of tissues under various environmental conditions in living subjects, enables to understand 
in-depth biological properties and roles of exosomes. We expect that the radiolabeled-exosomes will be 
gaining ground as a crucial imaging technique to apply exosomes to theranostics.
We reported a simple and rapid radiolabeling method of ENVs for in vivo radionuclide imaging, 
and imaged biodistribution of 99mTc-HMPAO-ENVs via SPECT/CT in living animals. Highly lipophilic 
99mTc-HMPAO which has been widely used for brain perfusion imaging agent was used for exosome 
labeling with simple and rapid reaction. Though this was a feasibility study of SPECT/CT images for 
exosomes, this approach has some limitations. Despite the high sensitivity of radiolabeled ENVs for 
noninvasive imaging (7.4–14.8 MBq of 29–64 μ g radiolabeled exosomes for imaging as described in 
Methods), labeling procedures can be improved more to reduce the loss of ENVs during labeling and 
separation especially for low-yield natural exosomes although we showed the possibility of SPECT/CT 
imaging of natural exosomes (Supplementary Fig. 3c). Furthermore, inhomogeneous vesicles derived 
from cell organelles would have contaminated the ENVs as ENVs were produced by extrusion of cells 
via polycarbonate membrane filters. Thus, further optimization of isolation techniques is warranted. 
Nevertheless, in vivo distribution of 99mTc-HMPAO-ENVs was clearly observed by SPECT/CT, showing 
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high radioactivity in the liver and spleen. The noninvasive imaging of radiolabeled ENVs and exosomes 
is promising approach to investigate in vivo behavior of exosomes and develop exosome-based drug 
delivery system.
Methods
Cell culture. Murine macrophage Raw 264.7 cell lines isolated from peritoneal fluid of BALB/c mouse 
was grown in Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen, Grand Island, NY). HB1.F3 
human neural stem cells immortalized by retroviral transduction with the v-myc oncogene were grown 
in DMEM. All media were supplemented with 10% fetal bovine serum (FBS) and 10 U/mL penicillin 
and 10 μ g/mL streptomycin (Invitrogen). All cells were cultured at 37 °C in a humidified atmosphere of 
5% CO2. Cell culture reagents were purchased from Gibco-BRL.
Preparation of ENVs from cell lines. After adherent Raw 264.7 and HB1.F3 cells were 
detached through gentle scraping, cells were resuspended at a concentration of 5× 106 cells/mL using 
phosphate-buffered saline (PBS). The cell suspension was extruded three times through 10, 5, and 
1 μ m-sized polycarbonate membrane filters sequentially using amini-extruder (Avanti Polar Lipids). To 
make density gradient step, 50% iodixanol (Axis-Shield PoC AS, Oslo, Norway) was firstly placed at the 
bottom of an ultracentrifuge tube with gentle loading, and 10% iodixanol was overlaid in the second step. 
The extruded samples were finally loaded, and then the prepared samples were spun at 100,000 × g for 
2 h at 4 °C using a Beckman Coulter type 45Ti rotor (Beckman Instruments, CA). ENVs were collected 
from the interface of the 50% and 10% iodixanol layers. And the produced ENVs were stored at − 20 °C.
Radiolabeling of ENV with 99mTc-HMPAO radiotracer. A commercially available kit of HMPAO 
was labeled with 99mTcO4− without methylene blue. A vial containing 0.5 mg HMPAO and 4.0 pg SnCl2 was 
reconstituted with 1110 MBq of 99mTcO4 in 5 mL of 0.9% NaCl solution and shaken for 10 s. After 5 min 
of incubation, 99mTc-HMPAO was immediately added to the prepared ENVs. The ENVs (100 μ g/100 μ l) 
were incubated for 1 hr with prepared 185–370 MBq of 99mTc-HMPAO at room temperature. During the 
incubation, the tube was slowly shaken until the end of labeling.
Isolation of 99mTc-HMPAO-ENVs from free 99mTc-HMPAO. Two different methods were used to 
remove 99mTc-HMPAO from free 99mTc-HMPAO-ENVs. A size exclusion column or centrifugation with 
exosome exclusive spin column was used for purification of radiolabeled ENVs. For the size exclusion 
column, 99mTc-HMPAO-ENVs were isolated using PD-10 column (GE Healthcare, Milwaukee, WI, USA) 
eluted with 0.9% w/v NaCl solution. The eluent was collected in test tubes of each 0.5 mL fraction. 
Radiochemical purity was measured by thin-layer chromatography (TLC) using Whatman no.1 paper 
and 0.9% w/v NaCl solution as an eluent for each column. Second, an exosome exclusive spin column 
with centrifugation was used (MW3000, Invitrogen). After the column was hydrated using 650 μ l of 0.9% 
w/v NaCl solution, excess interstitial fluid was removed by spinning the column at 750 × g for 2 min. 
The mixture of ENVs with 99mTc-HMPAO was centrifuged at 750 × g for 2 min at room temperature to 
isolate 99mTc-HMPAO-ENVs. The radioactivity was examined using an AR-2000 TLC imaging scanner 
(Bioscan, Washington, DC).
Serum stability study for 99mTc-HMPAO-ENVs. ENVs (100 μ g, 1 mg/ml in PBS) were incubated 
with 185 MBq 99mTc-HMPAO for 2 hr at room temperature. 99mTc-HMPAO-ENVs were immersed in PBS 
for 1.5 h to remove initial diffusion of lipophilic 99mTc-HMPAO from labeled-ENVs. 99mTc-HMPAO-ENVs 
were purified using exosome exclusive spin column. Samples loaded into 0.22 μ m-filtered human serum 
were incubated for 10 min, 30 min, 1 hr, 3 hr, and 5 hr. The radiochemical purity at serum condition in 
TLC was analyzed using 0.9% w/v NaCl solution as an eluent. Radiochemical purity was expressed as 
percentage of counter of 99mTc-HMPAO-ENVs.
Nanoparticle tracking analysis. The size distribution of ENVs prepared by Raw 264.7 cells was meas-
ured by the nano tracking analysis (NTA) method using a NANOSIGHT NS500 (Malvern, Grovewood 
road, UK) by using minor modification of manufacturer’s instruction. Samples were diluted sufficiently 
for the contrast and minimal background level. The quick measurement mode was performed to find 
the optimal condition. Then, total 5 numbers of particle motion video were recorded automatically using 
standard measurement mode (temperature: 22.9 °C and viscosity: 0.93 cP). The captured videos (5 videos 
per sample) were processed and analyzed (camera level: 4, capture duration: 60 s and detection threshold: 
7). All other conditions were constant. The graphical figure was automatically drawn by software and 
given excel data was used for the mean value and the standard deviation.
Glutathione assay of ENVs. Total glutathione content of ENV prepared by Raw 264.7 cells was 
determined by glutathione assay kit (Cayman Chemical, Ann Arbor, NY) according to the instruc-
tions of the manufacturer. Briefly, 100 μ g ENVs were resuspended and lysed in 0.1% Triton X-100 for 
30 min. After 15 min centrifugation at 10,000 × g at 4 °C, the supernatants were reacted with DTNB 
(5,5′ -dithiobis-2-nitrobenzoic acid) to produce yellow-colored TNB (-thio-2-nitrobenzoic acid) and the 
absorbance was read at 412 nm. To determine the concentration of glutathione, the reactions were carried 
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out with standard samples with known glutathione concentration. Three independent tests were carried 
out.
Western blot analysis. The concentration of prepared ENVs or 99mTc-HMPAO-ENVs was quanti-
fied using BCA protein quantification kit (Thermo Scientific, MA). ENVs or 99mTc-HMPAO-ENVs with 
equal amounts of protein were transferred onto PVDF membranes (Millipore, MA). PVDF membranes 
were blocked for 2 h at room temperature in Tris-buffered saline (TBS) containing 0.1% Tween20 and 
5% nonfat dried milk. PVDF membrane was probed with primary antibodies against anti-rabbit CD63 
(1:1000 dilution; Santa Cruz Biotechnology, TX) at 4 °C for overnight. PVDF Membranes were incu-
bated with HRP-labeled anti-rabbit secondary antibody for 2 hr at RT, and immunochemical detection 
was performed using chemiluminescence ECL detection system. Three independent experiments were 
performed in western blot assay.
In vivo SPECT/CT imaging of 99mTc-HMPAO-ENVs. All animal experiments were conducted 
according to the protocols approved by the Institutional Animal Care and Use Committee at Seoul national 
university hospital, Seoul, Republic of Korea (Approval number: 13-0265-COA1). 8 week-old male 
BALB/c mice (Koatech, Seoul, Korea) were bred in a pathogen-free facility at Seoul National University 
Hospital Biomedical Research Institute. Weight-matched mice were housed in laboratory animal care 
facility in cages (5 mice/cage) and fed a standard diet. For isolation of 99mTc-HMAPO-ENVs, the exosome 
exclusive spin column was used as aforementioned. 7.4–14.8 MBq of 29–64 μ g 99mTc-HMPAO-ENVs pre-
pared by Raw 264.7 cells (n = 3) and 11.1 MBq of 99mTc-HMPAO (n = 1) were injected into the tail vein. 
In addition, 4.4 MBq of 99mTc-HMPAO-ENVs prepared from HB1.F3 cells (30–35 μ g) were also injected 
(n = 2). After the administration of 99mTc-HMPAO-ENVs, serial SPECT/CT scans were acquired on a 
dedicated SPECT/CT scanner (NanoSPECT/CT, Bioscan, Washington, DC). All mice were anesthetized 
and maintained with 1.5% isoflurane at 1 L/min oxygen flow and placed on the prone position. The four 
multipinhole γ -detectors (9-pinholes) were used for high contrast collimation. Additional CT scans were 
acquired after SPECT acquisition for anatomical localization. Acquisition time was adjusted accord-
ing to the counts to be more than 30,000 counts per projection. For SPECT images, 24 projections 
were obtained into an 80 × 80 acquisition matrix. The images were reconstructed by a 3-dimensional 
ordered-subsets expectation maximum (OSEM) algorithm. The radioactivity in the organs was calculated 
in the SPECT images by volume-of-interest analysis. Counts were corrected for the decay of radioisotope 
and normalized by percent injected dose per gram (%ID/g).
In vivo biodistribution of 99mTc-HMPAO-ENVs. For biodistribution study, 74 kBq of 
99mTc-HMPAO-ENVs prepared by Raw 264.7 cells was injected into the tail vein of the mice (BALB/c, 
7–8 weeks old, n = 15). Mice were sacrificed after 0.5, 1, 3, and 5 h. Heart, lung, skeletal muscle, liver, 
spleen, stomach, intestine, kidneys, brain, bone and blood samples were taken and weighed. The radio-
activity of organs was determined by scintillation counting. The results were expressed as %ID/g.
Preparation of natural exosomes and SPECT/CT images. We extracted natural exosomes from 
Raw 264.7 cells. Complete DMEM cell medium was harvested after Raw 264.7 cells were incubated for 
24 hours with exosome-depleted FBS prepared by ultracentrifugation at 150,000 G for overnight. Cell 
debris from harvested cell medium was removed by serial centrifugation at 3,000 g for 15 min and 3,000 g 
for 20 min. Natural exosomes were purified by ultracentrifugation at 150,000 g for 2 hours at 4 °C. The 
collected exosome pellets were dissolved with PBS and the produced natural exosomes were stored at 
− 70 °C. The radiolabeling procedures were same as those of ENVs. 0.74 MBq of 15 μ g 99mTc-HMPAO 
labeled natural were injected into a BALB/c mouse and acquired SPECT/CT images as 99mTc-HMPAO 
ENVs SPECT/CT at 3 hr after the injection.
Ethics statement. All animal experiments were conducted according to the protocols approved by 
the Institutional Animal Care and Use Committee at Seoul national university hospital, Seoul, Republic 
of Korea (Approval number: 13-0265-COA1).
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